This Overlooked Biotech Giant Could Surprise Investors This Quarter

Biotech investors often chase early-stage companies in the hope that a single breakthrough trial will deliver massive returns. While those clinical-stage biotech stocks can offer enormous upside, they also come with outsized risk. However, sometimes established biotech companies like Gilead Sciences (GILD), which can deliver steadier and sometimes surprising growth, are overlooked. GILD stock has surged 22% so far this year, outperforming the broader market gain.

As Gilead prepares to report its fourth-quarter earnings on Feb 10, investors may be underestimating just how much momentum is building beneath the surface.